AnandShahFDA Profile Banner
Anand Shah, M.D. Profile
Anand Shah, M.D.

@AnandShahFDA

Followers
1K
Following
37
Media
12
Statuses
129

Former Deputy Commissioner for Medical and Scientific Affairs, U.S. Food & Drug Administration - This account is now archived.

Silver Spring, MD
Joined January 2020
Don't wanna be here? Send us removal request.
@AnandShahFDA
Anand Shah, M.D.
5 years
It was an honor and privilege to serve the American people. I’ll always be an advocate for FDA and public health. Signing off this account. Follow @AnandShahMD for updates.
3
0
12
@US_FDA
U.S. FDA
5 years
In a new episode of the #FDAInsight podcast, @FrankYiannasFDA joins @AnandShahFDA for a discussion on the New Era of Smarter Food Safety and how its blueprint impacts FDA’s #COVID19 response.
1
10
11
@US_FDA
U.S. FDA
5 years
In a new episode of the #FDAInsight podcast, Gail Bormel of FDA’s Center for Drug Evaluation and Research joins @AnandShahFDA for a discussion on drug compounding and its contribution to fighting #COVID19.
1
1
4
@AnandShahFDA
Anand Shah, M.D.
5 years
.@US_FDA is committed to ensuring that cutting-edge digital health technologies are rapidly developed. We've issued many policies to spur innovation during the #COVID19 pandemic. Here we discuss the implications for future U.S. digital health innovation.
1
13
29
@US_FDA
U.S. FDA
5 years
On #FDAInsight, Dr. Jeffrey Baker, from our Office of Biotechnology Products at CDER, joins @AnandShahFDA for a discussion on FDA’s efforts in advanced manufacturing.
1
4
8
@US_FDA
U.S. FDA
5 years
This week on #FDAInsight, RADM Richardae Araojo joins @AnandShahFDA to discuss the FDA’s efforts to address minority health disparities among diverse racial and ethnic populations.
5
5
13
@US_FDA
U.S. FDA
5 years
This week on #FDAInsight, Dr. Janet Maynard joins @AnandShahFDA for a discussion on our work advancing evaluation & development of products that demonstrate promise for the diagnosis & treatment of rare diseases.
2
4
16
@US_FDA
U.S. FDA
5 years
This week on #FDAInsight, Dr. Suzanne Schwartz joins @AnandShahFDA for a discussion on personal protective equipment and its critical role in helping to reduce the spread of #COVID19.
2
5
8
@US_FDA
U.S. FDA
5 years
Listen up! On today’s #FDAInsight, @AnandShahFDA welcomes CDER's Elizabeth Jungman to talk about hand sanitizers and #COVID19. Apple: https://t.co/yQ2FfaC9H7 Google: https://t.co/bWEfQbqM76 Pandora: https://t.co/5tYkCeMUtx Spotify:
2
2
4
@AnandShahFDA
Anand Shah, M.D.
5 years
In this episode of #FDAInsight, Dr. Peter Marks discusses the flu vaccine, how it works, @US_FDA's role in ensuring its safety, and the importance of getting vaccinated as soon as possible. Listen in here: https://t.co/TGkgk8ycts
3
3
7
@SteveFDA
Dr. Stephen M. Hahn
5 years
With the vaccines advisory committee meeting coming up this Thursday, now’s a great time to listen to this excellent podcast episode with a meeting primer from Dr. Peter Marks. #FDAInsight
Tweet card summary image
fda.gov
Dr. Peter Marks, FDA's Director of the Center for Biologics Evaluation and Research, returns for his third episode to provide an update on COVID-19 vaccines and to discuss the upcoming Vaccines and...
6
15
30
@AlecGaffney
Alexander Gaffney
5 years
FDA's @AnandShahFDA: FDA looking at possible regulatory lessons to take away from the pandemic, including: - ⬆️Use of decentralized trials using digital health platforms and home delivery of meds - ⬆️Use of RWE to inform future studies and patient exp. https://t.co/L6sDFkroap
Tweet card summary image
jamanetwork.com
This Viewpoint seeks to contextualize recent US Food and Drug Administration guidance on clinical trials during COVID-19 to oncology and to share insight regarding regulatory challenges and lessons...
0
2
3
@reaganudall
Foundation for FDA
5 years
A big thank you to FDA Commissioner @SteveFDA and Deputy Commissioners @DrAbernethyFDA, @AnandShahFDA, and @FrankYiannasFDA for sharing their expertise and insights today at our Annual Public Meeting.
1
4
8
@AnandShahFDA
Anand Shah, M.D.
5 years
Dr. Kaveeta Vasisht of @FDAWomen joins #FDAInsight to discuss the Office of Women's Health's work to advance the health of women through #FDA scientific programs, policy development, research, education and outreach. Check it out here:
1
3
5
@FDAOncology
FDA Oncology
5 years
Viewpoint: US Food and Drug Administration Support for Oncology Drug Development During COVID-19 by Kushal T. Kadakia, @AnandShahFDA and @realrickpazdur https://t.co/eJRBpHJogV via @JAMAOnc
0
6
9
@AnandShahFDA
Anand Shah, M.D.
5 years
Today on the #FDAInsight podcast, Dr. Steve Solomon (Director of @FDAanimalhealth) and I discuss antimicrobial resistance (#AMR) and @US_FDA's One Health approach to combatting AMR. You can listen here:
3
11
8
@US_FDA
U.S. FDA
5 years
LISTEN NOW: @DrMayneFDA from @FDAFood, joins #FDAInsight to discuss nutrition and chronic disease prevention. Subscribe on your favorite app… Apple: https://t.co/yQ2FfaC9H7 Google: https://t.co/bWEfQbqM76 Pandora: https://t.co/5tYkCeMUtx Spotify:
1
6
5
@AnandShahFDA
Anand Shah, M.D.
5 years
Mitch Zeller, Director of @FDATobacco, joins me in a #FDAInsight discussion on e-cigarettes (or vapes) and the 2020 National Youth Tobacco Survey results. Learn more about @US_FDA's efforts to protect Americans from tobacco-related death and disease.
8
5
10
@AnandShahFDA
Anand Shah, M.D.
5 years
On the latest episode of #FDAInsight, you'll learn about @US_FDA's role in fighting the opioid crisis from Megan Moncur, Associate Director of Opioid Policy (@FDA_Drug_Info). She shares timely advice for patients and consumers. Check it out here:
2
6
6
@AnandShahFDA
Anand Shah, M.D.
5 years
Great news for seniors' access to innovative medical products. The proposed @CMSGov Medicare Coverage of Innovative Technology pathway accelerates coverage for @US_FDA breakthrough products. Medicare would provide 4 years of national coverage simultaneously with FDA approval.
@SeemaCMS
Administrator Seema Verma
5 years
America’s seniors deserve access to the same cutting-edge medical technology that others get. Today’s rule cuts out bureaucratic wrangling that often acts as a “valley of death” between the costly process of getting a product approved by the FDA and getting Medicare coverage.
3
6
18